Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and QT Interval for Healthy Subjects Who Received Placebo in Phase I Trials by Mukul Minocha, Hong Li, Yi‐Lin Chiu, David Carter, Ahmed A. Othman

Get full text

Evaluation of the potential for pharmacokinetic interaction between tirabrutinib and levonorgestrel/ethinyl estradiol in healthy female volunteers by Ganesh Cherala, Cara Nelson, Ying Guo, Anubhav Mathur, Thomas Tarnowski, Ahmed A. Othman

Get full text

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers by Islam R. Younis, Brian J. Kirby, Andrew N. Billin, Deqing Xiao, Qinghua Song, Timothy R. Watkins, Ahmed A. Othman

Get full text

Pharmacokinetics, pharmacodynamics, and safety of GS‐3583, a FLT3 agonist Fc fusion protein, from single‐ascending‐dose phase I study in healthy participants by Anees M. Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, Winnie Weng, Kai‐Wen Lin, Emon Elboudjwarej, Ann Ran‐Ran Qin, Christian Schwabe, Michelle R. Kuhne, Ahmed A. Othman

Get full text

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors by Michael Gordon, Anthony W Tolcher, James Strauss, Marianna Zavodovskaya, Anna Seto, Tianling Chen, Susanna Stinson, Kathleen M Mahoney, Chia-Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M Jürgensmeier, Ahmed A Othman

Get full text

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors by Nicholas Waldron, P Rod Dunbar, Sanjeev Deva, Oh Kyu Yoon, John Ling, Kai-Wen Lin, Dung Thai, Latesh Lad, Ahmed A Othman, Jared M Odegard, Adele Y Wang, Jonathan Nazareno, Edmond Ang

Get full text